Sinopharm Device Subsidiary Boosts Profit and Cash Flow Despite Lower 2025 Revenue

Sinopharm Group Co ( (HK:1099) ) has provided an update.

Sinopharm Group disclosed the 2025 audited financial results of its medical device subsidiary CNMDC, showing revenue of RMB 74.89 billion, down 2.35% year on year, while operating profit edged up 2.38% to RMB 1.25 billion. Total comprehensive income attributable to the parent’s owners rose 25.64% to RMB 506.76 million and equity attributable to the parent increased 5.27%, even as total assets declined 7.07%.

CNMDC’s operating cash flow swung sharply from a negative RMB 1.36 billion in 2024 to a positive RMB 738.64 million in 2025, indicating a significant improvement in cash generation despite slightly lower sales. The combination of stronger profitability, improved cash flow and higher equity suggests enhanced financial resilience for Sinopharm’s device arm, which may support its competitiveness and strategic flexibility in China’s medical device sector.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

More about Sinopharm Group Co

Sinopharm Group Co. Ltd. is a major Chinese healthcare conglomerate with operations spanning pharmaceutical distribution and medical devices, serving hospitals, clinics and other healthcare institutions. Through its subsidiary China National Medical Device Co., Ltd. (CNMDC), the group focuses on the manufacture, distribution and related services of medical equipment and consumables in mainland China’s healthcare market.

Average Trading Volume: 5,305,954

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$65.72B

Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.